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Abstract
Background This study evaluates differences in smoking
abstinence between white and minority smokers using
pharmaceutical aids.
Methods This is an analysis of data from a multi-center,
randomized, clinical trial conducted in the United States. Of
the 1,684 subjects randomized to one of three medications
(nicotine inhaler, bupropion, or a combination of both),
60% were women and 10% were minority races.
Results Factors associated with a decreased likelihood of
smoking at 12 weeks were older age (OR = 0.971, p<
0.0001), being married (OR = 0.678, p=0.0029), using
bupropion SR (OR = 0.480, p<0.0001), and using
combination therapy (OR = 0.328, p<0.0001). Factors
associated with an increased likelihood of smoking were
higher tobacco dependence scores (OR = 1.244, p<0.0001),
prior quit attempts (OR = 1.812, p=0.004), and being a
minority (OR = 1.849, p=0.0083). Compared to white
smokers, minority smokers were significantly older at time
of study entry (46 vs. 42 years, p<0.0001), less likely to be
married (35% vs. 59%, p<0.0001), older at smoking
initiation (21 vs. 19 years of age, p<0.0001), and had a
lower abstinence rate (16% vs. 26%, p=0.0065).
Conclusion Regardless of the treatment used, minority
smokers in the US have lower smoking abstinence after
treatment for tobacco dependence. Future research should
focus on the improvement in treatment strategies for
minority smokers.
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Abbreviations
BMI Body Mass Index
CO carbon monoxide (expired air)
COPD chronic obstructive pulmonary disease
FCTC WHO Framework Convention on Tobacco
Control
FTND Fagerström test of nicotine dependence
HSQ Health Status Questionnaire
NCCTG North Central Cancer Treatment Group
NCI National Cancer Institute
NIH National Institutes of Health
MAOI monoamine oxidase inhibitor
PPM parts per million
TQD target quit day
USPHS United States Public Health System Service
Introduction
Globally, about one in three men smoke, and one in ten adults
die annually from tobacco-related diseases. As the smoking
rates in the developed countries continue to reduce, the rate in
developing countries continues to rise (World Health Organi-
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DOI 10.1007/s10389-009-0277-2zation 2002). Indeed, part of the preamble to the WHO
Framework Convention on Tobacco Control (FCTC) dis-
cusses the “deep concern about the escalation in smoking and
other forms of tobacco consumption by indigenous popula-
tions and other minority groups worldwide.” The FCTC also
mentions the “need to take measures to promote the
participation of indigenous individuals and communities in
the development, implementation and evaluation of tobacco
controlprogramsthataresociallyandculturallyappropriateto
their needs and perspectives” (World Health Organization
2000).
Currently, 19.8% of Americans or one out of every four
Americans is a current smoker (Centers for Disease Control
and Prevention 2008). Unfortunately this statistic does not
apply equally to all races living in the USA. The smoking rate
in the USA can vary from 12% to 33% depending on the race
of the smoker. This translates to one out of every four white
Americans, one out of every four African Americans, two out
ofeverythreeAmericanIndians/AlaskanNatives,andoneout
of eight Asian Americans being smokers (American Lung
Association et al. January 2006; Center for Disease Control
and Prevention 2006). Although over 70% of all smokers
indicate a desire to stop smoking, it is noteworthy that
African-American adults, who smoke fewer cigarettes and
have more frequent quit attempts than white smokers (49%
vs. 40%, respectively), are less successful (8% vs. 14%,
respectively) in achieving smoking abstinence than white
smokers (Center for Disease Control and Prevention 1993).
Whether this is attributable to differences in nicotine
metabolism (Murray et al. 2001) or environmental circum-
stances is unknown, but the fact remains that despite smoking
fewer cigarettes per day, African Americans are 50% more
likelytodie fromlungcancerthantheirwhite counterpart (US
Department of Health and Human Services 1998).
An earlier study that offered a nicotine inhaler, bupro-
pion SR, or a combination of both for 12 weeks to smokers
wishing to stop smoking (Croghan et al. 2007) observed
that smokers assigned to the combination therapy were
more likely to be abstinent than those assigned to individual
therapies. However, this study also showed that the
smoking abstinence rate for minority smokers was signif-
icantly lower than that of the white smokers. The purpose
of this current report is to analyze the study data as they
relate to minority smokers enrolled in the open-label phase
of this study.
Methods
Study subjects
This study recruited smokers from 19 different cities of the
North Central Cancer Treatment Group (NCCTG). The
NCCTG is a large cooperative group of oncology practices
throughout the USA that performs multiple clinical trials in
oncology patients. A total of 1,708 smokers were recruited
from the general population, and 1,700 were randomized to
the study.
Among these 1,700 smokers, 16 were of Hispanic
ethnicity, and 1,684 were non-Hispanic. Of the 1,684
non-Hispanic smokers, 1,512 were white and 172 were
minority races (138 were African American and 34 were
other races, including Asian-American, American Indian,
and Hispanic-American).
Study design
This report is a subanalysis of a larger study involving three
study phases. The first phase included 12 weeks of open-
label medication to measure efficacy; the second phase
assessed blinded relapse prevention or blinded re-treatment;
finally, a third phase was the post-medication follow-up.
Methodology and results of this larger study have been
reported previously (Croghan et al. 2007).
This current report focuses only on the 1,684 non-
Hispanic participants who received the first 12 weeks of
medication. Study participants were randomized to receive
one of three treatment assignments for 12 weeks: 300 mg of
bupropion SR per day (150 mg bid), ad libitum use of a
nicotine inhaler (up to 16 cartridges per day), or a
combination of both the nicotine inhaler and bupropion.
The primary endpoint for the study was the smoking status
at the end of the treatment period.
Study entry criteria
Potential subjects were eligible for enrollment if they were
at least 18 years of age, had smoked at least ten cigarettes/
day for at least 12 months, were motivated to use the
study medication according to the study protocol, were
in general good health, had the ability to participate in
all aspects of the study, and provided written informed
consent. Potential subjects were excluded if they were
pregnant/breast-feeding, using concurrent behavioral/
pharmacologic treatments to stop smoking, using tobac-
co products other than cigarettes, or taking an investi-
gational drug. Subjects were also excluded if they had a
known hypersensitivity/allergy to nicotine, bupropion, or
menthol, unstable angina/myocardial infarction, a history
of bulimia/anorexia nervosa, seizure disorders, serious
head trauma or other predisposing factors to seizure, or
chemical dependence on any drug other than nicotine in
the past year. Subjects were also excluded if they were
using antipsychotics, antidepressants, theophylline, sys-
temic steroids, antiepileptic medications, or a mono-
amine oxidase inhibitor (MAO-I).
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Recruitment for this large study included smokers contact-
ing their regional North Central Cancer Treatment Group
site and undergoing a telephone pre-screen, consent visit
and a screening visit. If the smoker was found to be
eligible, they were randomized to one of three medications.
After randomization, participants returned for study visits at
week 4, week 8, and week 12 post-randomization. The
subjects were instructed to abstain from smoking upon
awakening on the target quit date. All subjects received the
NCI “Clearing the Air” booklet and individual counseling
based on the “Smoke Free and Living It” manual© (Mayo
Clinic Nicotine Research Program 2000).
Study measures
The National Institutes of Health (NIH) define ethnicity as
the sociological constructs that emphasize the cultural
aspect of a group of people, and race is defined as a
biological aspect of a group of people (Crews and Bindon
1991; O'Neil 2008). This study uses this definition, which
distinguishes between someone’s ethnic origins ("Hispanic
origin" and "Not of Hispanic origin") and race (“American
Indian or Alaskan Native,”“ Asian or Pacific Islander,”
“Black or African American,” and “White”) (Executive
Office of the President et al. 2007).
Severity of nicotine dependence was assessed at baseline
using the Fagerström Test of Nicotine Dependence (FTND)
(Heatherton et al. 1991). Scores for this measure can range
from 0 to 10, with a score of 6 or higher indicating severe
nicotine dependence (Fagerström 1978). The Health Status
Questionnaire (HSQ) (Ware and Sherbourne 1992) is a 39-
item instrument comprised of the original SF-36 items plus
three additional items used to screen for depression
(Radosevich et al. 1994). The SF-36 is a global assessment
of health concepts that represent basic human values relevant
tofunctionalstatusandwell-being(Wareetal.1993). Alcohol
dependence was assessed using the Self-Administered
Alcoholism Screening Test (SAAST) (Hurt et al. 1980).
Abstinence from smoking was defined as a self-report of
nonsmoking for the previous 7 days and was considered to
be biochemically confirmed with an expired air carbon
monoxide value below eight parts per million (ppm). If the
participant failed either of these two conditions (reported
any smoking in the previous 7 days or had a CO greater
than 8 ppm) then the participant was categorized as a
smoker. In order to produce a conservative estimate of
smoking abstinence, study outcome data were analyzed in
an intent-to-treat model. If a participant failed to complete a
visit for whatever reason (missed a visit or terminated early
from the study), the participant was classified as a smoker
for that incomplete visit.
Randomization and statistical analysis
Randomization was performed using the Pocok-Simon
approach, which is a dynamic allocation procedure that
balanced the marginal distributions of the stratification
factors between treatment groups (Pocock and Simon
1975). Stratification factors were: site, gender, number of
cigarettes smoked per day (10–39 vs. 40 or more), and
number of years smoked (<5, 5–9, >9). Randomization
assigned subjects to one of three medications.
Demographics and smoking abstinence rates at
12 weeks were compared using chi-square tests for
categorical variables and ANOVA for continuous varia-
bles. Comparisons were done between blacks and other
minorities to determine if minorities were similar enough
to be combined in the main analyses. The main analyses
were comparisons between whites and the combined
minorities.
The primary endpoint of this study was the week 12, 7-day
point-prevalence, biochemically confirmed, smoking absti-
nence rate. These cessation rates were tested using two-sided
chi-squared tests. With about 172 minorities and over 1,500
whites, this study had 80% power to detect a clinically
significant 10% point difference in smoking abstinence rates
between the two groups (assuming a baseline success rate of
25% for each of the treatments).
Logistic regression
Smoking cessation rates at week 12 were modeled using
logistic regression. First, bivariate logistic regression
models were fit for each explanatory variable. Then
stepwise logistic regression models were used to identify
variables prognostic for smoking cessation. Variables were
added to the model one at a time in a stepwise method with
an inclusion significance level of 0.05. Variables included
for selection in the logistic models were minority, treatment
arm, age, age started smoking, years smoked, gender,
education, marital status, number of cigarettes smoked per
day, depression status, FTND, body mass index (BMI),
previous quit attempts, previous use of nicotine replace-
ment, and the longest duration of smoking abstinence. To
assess whether differences between race groups were
dependent on treatment, the race-by-treatment interaction
effect was added to the final model determined using the
stepwise approach.
Results
Of the 1,684 smokers analyzed for this report, 172 (10%)
were of the four minority races, and 1,512 (90%) were
white. A comparison of demographics and abstinence rates
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significant difference existed between the diverse minorities
enrolled in this study. The results in Table 1 show that
blacks and other minorities were not significantly different
on any of the baseline characteristics or in smoking
abstinence rates. The smoking abstinence rates at end of
medication were 25% (2/8) for the Asians, 16% (22/138)
for the African Americans, 11% (2/19) for the Native
Americans, and 29% (2/7) for the other participants. For
this reason and in order to increase our study power, we
combined the four minority populations and made a larger
comparison of the minority population with the white
smokers.
Table 2 presents the demographics of this study
population. In comparison to whites, minority smokers
were significantly older in age at the time of study entry
(46 years of age versus 42 years of age, minorities and
white, respectively, p<0.0001), less likely to be married
(35% versus 59%, minorities and white, respectively, p<
0.0001), older when they began smoking (22 years of age
versus 19 years of age, minorities and white, respectively,
p<0.0001), smoked fewer cigarettes per day at baseline (19
versus 24, minorities and white, respectively, p<0.0001),
and were less likely to have stopped smoking at the end of
the 3 months of medication treatment (16% abstinent versus
26% abstinent, minorities and white, respectively, p=
0.0065). Figure 1 shows abstinence rates by race within
each treatment arm.
Bivariate logistic model results
Smoking abstinence rates at week 12 were modeled
using bivariate logistic models as shown in Table 3.
Variables independently associated with lower abstinence
rates were: smoking 40 or more cigarettes per day at
baseline (OR = 1.498, p=0.0396), an FTND score (OR =
1.197, p<0.0001), major depression (OR = 1.357, p=
0.0408), ever attempted to stop smoking before this study
(OR = 1.853, p=0.0011), and being a minority race (OR =
1.781, p=0.0072). Variables associated with higher absti-
nence rates were treatment (bupropion OR = 0.489,
combination OR = 0.323, p<0.0001), age (OR = 0.976,
p<0.0001), age started smoking (OR = 0.976, p=0.0070),
being married (OR = 0.623, p<0.0001), and having quit
smoking before this study for at least 1 day (OR = 0.601,
p=0.0083).
Multivariate logistic model results
A multivariate logistic regression model (Table 4) showed
that when controlling for all other significant factors, the
following were found to be predictive of smoking absti-
nence after 12 weeks of pharmacotherapy: the younger the
age, the greater was the likelihood to be abstinent (OR =
0.971, p<0.0001); those who were married were more
likely to be abstinent from smoking (OR = 0.678, p=
0.0029); using bupropion was associated with greater
abstinence from smoking (OR = 0.480, p<0.0001); using
a combination of bupropion and nicotine inhaler was also
associated with greater abstinence from smoking (OR =
0.328, p<0.0001); conversely, the higher the FTND score,
the greater the likelihood to be a continuing smoker (OR
1.244, p<0.0001); having any prior quit attempts indicated
greater likelihood to be a continuing smoker (OR = 1.812,
p=0.004); being a minority was associated with continued
smoking (OR = 1.849, p=0.0083).
In order to assess whether differences between race
groups was dependent on treatment, an initial model was fit
that included all main effect terms along with the race-by-
treatment interaction effect. From this analysis the race-by-
treatment interaction was not found to be statistically
significant (p=0.8113). Therefore, the findings presented
here are from the model that includes only main effect
terms.
Discussion
Main findings
Our study compared the nicotine inhaler and bupropion
versus the combination of the two in a large number of
smokers, of which 10% were minority smokers. We
observed that minority smokers were less likely to stop
smoking at the end of 12 weeks of treatment when
compared to white smokers.T h i si sc o n s i s t e n tw i t h
current US data indicating that overall smoking absti-
nence rates among white smokers is higher than that of
the minority smokers who are trying to quit (Croghan et
al. 2008a; U.S. Department of Health and Human Services
1998).
Predictors of smoking abstinence at end of treatment
(12 weeks) include younger age at the time of the quit
attempt, being married at the time of study participation
(and quit attempt), less severe tobacco dependence based
on lower FTND scores, fewer past smoking quit attempts,
using bupropion (either alone or in combination with
inhaler), and being white. Demographics of the study
population indicate that at the time of enrollment, minority
subjects enrolled in this study were more likely to be older
and less likely to be married. Minority smokers enrolled in
our program also reported being older when they started
smoking and smoking fewer cigarettes per day at time of
study enrollment.
In our study we did not find any evidence to suggest that
treatment efficacy differed according to race (i.e., no
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Black (N=138) Other (N=34) Total (N=172) p value
Age 0.0688
Mean (±SD) 47.1 (10.37) 43.2 (14.38) 46.3 (11.33)
Gender 0.2738
Female 91 (65.9%) 19 (55.9%) 110 (64%)
Male 47 (34.1%) 15 (44.1%) 62 (36%)
Marital status 0.0846
Missing 1 0 1
Never married 31 (22.6%) 5 (14.7%) 36 (21.1%)
Married 42 (30.7%) 18 (52.9%) 60 (35.1%)
Separated/divorced/widowed 62 (45.3%) 10 (29.4%) 72 (42.1%)
Other 2 (1.5%) 1 (2.9%) 3 (1.8%)
Education 0.2989
Missing 1 0 1
Less than HS 6 (4.4%) 3 (8.8%) 9 (5.3%)
HS or greater 131 (95.6%) 31 (91.2%) 162 (94.7%)
Age started smoking 0.1071
Mean (±SD) 22.0 (±7.00) 19.8 (±7.51) 21.5 (±7.14)
Month 0: CPD 0.1355
Mean (±SD) 18.5 (±8.90) 21.1 (±9.40) 19.0 (±9.03)
Years smoking cigarettes 0.4394
Mean (±SD) 25.1 (±10.42) 23.4 (±14.87) 24.8 (±11.42)
Ever tried to stop smoking 0.7615
Missing 1 1 2
1: Yes 119 (86.9%) 28 (84.8%) 147 (86.5%)
2: No 18 (13.1%) 5 (15.2%) 23 (13.5%)
Number of times tried to stop 0.4487
Mean (±SD) 3.9 (±3.76) 3.3 (±3.66) 3.8 (±3.74)
Overall Fagerström score 0.5900
Mean (±SD) 5.8 (±1.88) 5.6 (±2.12) 5.7 (±1.93)
Fagerström groups 0.2584
Missing 5 0 5
1–4 (low) 34 (25.6%) 12 (35.3%) 46 (27.5%)
5–6 (med) 55 (41.4%) 9 (26.5%) 64 (38.3%)
≥7 (high) 44 (33.1%) 13 (38.2%) 57 (34.1%)
HSQ major depression 0.3641
Missing 3 2 5
No 104 (77%) 27 (84.4%) 131 (78.4%)
Yes 31 (23%) 5 (15.6%) 36 (21.6%)
HSQ mental composite month 3 minus baseline 0.5341
Mean (±SD) 1.8 (±7.97) -0.3 (±7.15) 1.3 (±7.72)
HSQ physical composite month 3 minus baseline 0.0984
Mean (±SD) 3.3 (±6.64) -1.9 (±8.52) 2.1 (±7.31)
Week 12: confirmed nonsmoker 0.8094
No 116 (84.1%) 28 (82.4%) 144 (83.7%)
Yes 22 (15.9%) 6 (17.6%) 28 (16.3%)
Arm 0.5034
Nicotine inhaler 42 (30.4%) 8 (23.5%) 50 (29.1%)
Bupropion 54 (39.1%) 17 (50%) 71 (41.3%)
Combination treatment 42 (30.4%) 9 (26.5%) 51 (29.7%)
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may be less accepting of nicotine replacement products
than white smokers (Fu et al. 2005). Latino smokers have
been observed to use pharmaceutical aids less often than
white smokers (Levinson et al. 2004). Because drug
accountability was not collected in our study, we cannot
assess for this. However, we did demonstrate that the two
treatments were predictive of smoking abstinence in
minority smokers. This is similar to another report where
bupropion with active nicotine gum or bupropion with
placebo nicotine gum was more effective among minority
smokers than placebo bupropion and placebo nicotine gum
(Piper et al. 2007). Furthermore, bupropion has been shown
to help African-American smokers to stop smoking at
higher rates compared to placebo (Ahluwalia et al. 2002;
Robles et al. 2008).
Conclusions
Because minority groups have disproportionately greater
health problems related to smoking than do whites, some
Table 2 Demographics of study population*
Minority (N=172) White (N=1,512) Total (N=1,684) p value
Age at randomization (mean ± SD) 46.3 (±11.33) 42.4 (±11.49) 42.8 (±11.53) <0.0001
Gender 0.2278
Female 110 (64.0%) 895 (59.2%) 1005 (59.7%)
Male 62 (36.0%) 617 (40.8%) 679 (40.3%)
Marital status <0.0001
Never married 36 (21.1%) 211 (14%) 247 (14.7%)
Married 60 (35.1%) 894 (59.3%) 954 (56.9%)
Separated/divorced/widowed 72 (42.1%) 381 (25.3%) 453 (27%)
Other 3 (1.8%) 21 (1.4%) 24 (1.4%)
Education 0.1747
Less than HS 9 (5.3%) 63 (4.2%) 72 (4.3%)
HS or greater 162 (94.7%) 1,410 (94%) 1,572 (94.1%)
Other 0 (0%) 27 (1.8%) 27 (1.6%)
Age started smoking (mean ± SD) 21.5 (±7.14) 18.7 (±5.85) 19.0 (±6.05) <0.0001
Cigarettes per day at baseline (mean ± SD) 19.0 (±9.03) 23.6 (±9.84) 23.2 (±9.86) <0.0001
Years of regular smoking (mean ± SD) 24.8 (±11.42) 23.7 (±11.20) 23.8 (±11.22) 0.2414
Any prior quit attempts 147 (86.5%) 1,299 (86.3%) 1,446 (86.3%) 0.9383
Prior quit attempts (mean ± SD) 3.8 (±3.74) 3.4 (±3.87) 3.4 (±3.86) 0.2271
Overall Fagerström score (mean ±SD) 5.7 (±1.93) 5.8 (±2.16) 5.8 (±2.14) 0.5157
Fagerström score 0.2341
1–4 (low) 46 (27.5%) 408 (27.6%) 454 (27.6%)
5–6 (med) 64 (38.3%) 478 (32.4%) 542 (33.0%)
≥7 (high 57 (34.1%) 590 (40%) 647 (39.4%)
HSQ: major depression 36 (21.6%) 296 (20.3%) 332 (20.5%) 0.7096
HSQ mental composite: month 3–baseline (mean ± SD) 1.3 (±7.72) -1.2 (±8.46) -1.1 (±8.43) 0.1144
HSQ physical composite: month 3–baseline (mean ± SD) 2.1 (±7.31) 1.2 (±6.93) 1.3 (±6.95) 0.5015
Smoking abstinence at month 3 (week 12) 28 (16.3%) 389 (25.7%) 417 (24.8%) 0.0065
Treatment arm 0.0672
Nicotine inhaler 50 (29.1%) 512 (33.9%) 562 (33.3%)
Buproprion 71 (41.3%) 491 (32.5%) 562 (33.4%)
Nicotine inhaler + bupropion 51 (29.7%) 509 (33.7%) 560 (33.3%)
*Study population for this report is limited to those not of Hispanic origin
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ization of health-care options may help reduce some of this
disproportion (Dundas et al. 2001; Houston et al. 2005;
Shah and Cook 2008). In a study by White et al., it was
found that despite the fact that British ethnic minorities
(Bangladeshi and Pakistani) had high motivation to quit
smoking, the barriers were too many to overcome (White et
al. 2006). The many barriers named include: perceived
barriers such as peer pressure, stresses, withdrawal, lack of
accessibility to health care for smoking cessation and lack
Table 3 Bivariate logistic regression models for smoking rates at 12 weeks*
Variable Odds ratio (smoking) 95% confidence intervals for the odds ratio p-value
Age† 0.976 0.967 to 0.986 <0.0001
Age started smoking† 0.976 0.960 to 0.993 0.0070
Marital status <0.0001
Not married 1.000
Married 0.623 0.494 to 0.784
Fagerström score† 1.197 1.134 to 1.263 <0.0001
Prior quit attempt 0.0011
No 1.000
Yes 1.853 1.279 to 2.684
Quit before for at least 1 day 0.0083
No 1.000
Yes 0.601 0.412 to 0.877
40 or more cigarettes per day at study entry 0.0396
No 1.000
Yes 1.498 1.019 to 2.202
Major depression 0.0408
No 1.000
Yes 1.357 1.013 to 1.819
Treatment <0.0001
Nicotine inhaler 1.000
Bupropion 0.489 0.361 to 0.661
Combination treatment 0.323 0.241 to 0.433
Gender 0.0681
Female 1.000
Male 0.812 0.649 to 1.016
Education beyond high school 0.8938
No 1.000
Yes 0.984 0.771 to 1.255
BMI† 0.990 0.973 to 1.008 0.2858
Tried prior nicotine 0.8026
No 1.000
Yes 0.972 0.778 to 1.214
Number of years smoked 0.4885
Less than 5 Years 1.047 0.600 to 1.827
At least 5 years but less than 10 years 1.000
10 years or more 0.825 0.581 to 1.172
Race 0.0072
White 1.000
Minority 1.781 1.169 to 2.714
†Age, age started smoking, BMI, and Fagerstrom score were treated as continuous variables. For these variables the odds ratio presented is for a
one-unit increase (i.e., per 1-year increase in age). All other characteristics were treated as categorical variables. For these characteristics an odds
ratio of 1.000 is used to indicate the reference group. Odds ratios >1.000 indicate an increased likelihood of smoking at 12 weeks
J Public Health (2010) 18:59–68 65of pharmaceutical aids; the health-care community believed
that language, religion, and culture contributed to reduced
smoking cessation health care among this population.
Despite the fact that this study by White et al. (2006) took
place in Britain and our study was in the USA, the issues
with health care among minorities in our respective nations
is still the same. It can be hypothesized that the lower rates
of smoking abstinence among minority smokers may be
explained by reduced health care, possibly due to econom-
ics, misconceptions, lack of communication, and/or lack of
cultural understanding by health-care providers (Fu et al.
2007; King et al. 1997). The various options of tobacco
dependence treatment should be explored with the individ-
ual smokers for acceptability as well as to meet individual
needs (White et al. 2006). Currently, treatment for a general
smoker who is considered a “light” smoker (<15 cigarettes
per day) is not the same as that for a “heavy” smoker (>25
cigarettes per day), but as is evident in this study, the
number of cigarettes per day should not be the sole
deciding factor in determining the type and intensity of
treatment a smoker receives. A more targeted approach to
the role of behavioral interventions in the treatment of
smokers has been evaluated in the past (Fernander et al.
2006), but a targeted approach that considers racial and
cultural differences that can lead to acceptability of and
compliance with treatment for medical interventions has yet
to be examined (Lillard et al. 2007; White et al. 2006). In a
current study from a clinical treatment program, it was
found that whereas gender differences existed in those
enrolling in a formal treatment program, gender did not
ultimately affect smoking abstinence at 6 months. It was
hypothesized that this could possibly be due to individual-
ization of the treatment program for each patient (Croghan
et al. 2008b). An overall targeted approach in the medical
management of tobacco dependence (behavioral and med-
ical intervention) may also be the preferred approach in
minority smokers.
Limitations
This study was designed to mimic a “real-life” situation as
much as possible. Although this reasoning was noteworthy,
it limited the investigation results. Limitations to this study
include the facts that all study sites were within the USA
and that study subjects were all volunteers and may not be
representative of minority smokers in the general global
population. In addition, no data were collected regarding
the frequency and patterns of medication use. Whereas all
subjects were instructed on the proper use and dosing of all
study medication, no tracking of their actual use was
conducted, nor was their acceptability of the medication
assigned to them or their comprehension of the instructions
documented. In addition, no follow-up or data capture took
Table 4 Multivariate logistic regression model for smoking rates at 12 weeks*
Variable† Odds ratio (smoking) 95% Confidence intervals for the odds ratio p-value
Age 0.971 0.960 to 0.982 <0.0001
Marital status 0.0029
Not married 1.00
Married 0.678 0.525 to 0.876
Fagerström score 1.244 1.172 to 1.320 <0.0001
Prior quit attempt 0.0044
No 1.000
Yes 1.812 1.203 to 2.728
Treatment† <0.0001
Nicotine inhaler 1.000
Bupropion 0.480 0.348 to 0.663
Combination treatment 0.328 0.240 to 0.450
Race† 0.0083
White 1.000
Minority 1.849 1.171 to 2.919
*In order to assess whether differences between race groups was dependent on treatment, an initial model was fit that included all main effect
terms along with the race-by-treatment interaction effect. From this analysis the race-by-treatment interaction was not found to be statistically
significant (p=0.8113). Therefore, the findings presented here are from the model that includes only main effect terms
†Age and Fagerstrom score were treated as continuous variables. For these variables the odds ratio presented is for a one-unit increase (i.e., per
1-year increase in age). All other characteristics were treated as categorical variables. For these characteristics an odds ratio of 1.000 is used to
indicate the reference group. Odds ratios >1.000 indicate an increased likelihood of smoking at 12 weeks
66 J Public Health (2010) 18:59–68place concerning any additional medications or behavioral
counseling the subject may have used outside the study.
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